IONIS PHARMACEUTICALS INC — Form 8-K
Filed September 4, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 62/100
What the filing says
Novartis announced that the Lp(a)HORIZON Phase 3 trial of pelacarsen (discovered and developed by Ionis, licensed to Novartis in February 2019) failed its primary endpoint of reducing cardiovascular events in 8,323 patients with elevated Lp(a) and established CVD. While pelacarsen achieved substantially lower Lp(a) levels, this did not translate to cardiovascular risk reduction. No financial terms, payment impacts, or asset write-downs are disclosed in this announcement.
Why this rating
Pelacarsen was a material Ionis asset (licensed 2019); trial failure eliminates near-term revenue potential and raises questions about Lp(a) biology. No milestone/royalty figures disclosed, so impact size unclear relative to $5.3B market cap—but loss of a late-stage asset is significant.
See more from September 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.